NBIX · Neurocrine Biosciences Inc
United States · RS rating 84 · As of 2026-11-03
| Price | 164.85 USD |
|---|---|
| 1-day change | +13.4% |
| RS rating (overall / 1M / 3M / 12M) | 84 / 89 / 71 / 64 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 42 / 39 / 46 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -27.4% |
| Sales growth Q/Q | +1.3% |
| Distance from 52-week high | +11.1% |
| Market cap (USD) | $13.1B |